Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Income from Continuing Operations (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Income from Continuing Operations data on record, last reported at 38804000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 3.03% year-over-year to 38804000.0; the TTM value through Dec 2025 reached 101590000.0, up 22.03%, while the annual FY2025 figure was 101594000.0, 22.03% up from the prior year.
  • Income from Continuing Operations reached 38804000.0 in Q4 2025 per TNGX's latest filing, down from 15874000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 15874000.0 in Q3 2025 and bottomed at 39842000.0 in Q1 2025.
  • Average Income from Continuing Operations over 5 years is 24819330.05, with a median of 26779500.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: plummeted 157442.58% in 2021, then soared 154.42% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 22046000.0 in 2021, then tumbled by 31.82% to 29060000.0 in 2022, then decreased by 5.82% to 30750000.0 in 2023, then fell by 22.48% to 37662000.0 in 2024, then decreased by 3.03% to 38804000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 38804000.0 in Q4 2025, 15874000.0 in Q3 2025, and 38818000.0 in Q2 2025.